Open Access Open Access  Restricted Access Subscription or Fee Access

Bacteriophage and its Potential for Therapeutic Use in Brucellosis among Cattles

Hari Mohan Saxena

Abstract


Bacteriophages are viruses that can specifically kill certain bacteria. This property of phages can be exploited for therapeutic application in treating bacterial infections in domestic animals. Brucellosis is an important zoonotic disease which is endemic in several countries. Antibiotics are not very effective against bovine brucellosis and the cost of this treatment is very high. Lytic phages against Brucella have been isolated and have been tried for therapy of bovine brucellosis with encouraging results. The present study reviewed the studies on bacteriophages with special reference to Brucellaphage and their application in the therapy of bovine brucellosis.


Keywords


Bacteriophage, Brucellaphage, phage therapy, phage lysate, bovine brucellosis

Full Text:

PDF

References


d’Herelle F. The bacteriophage. Science News. 1949; 14: 44–59p.

Gabashvili I, Khan S, Hayes S, Serwer P. Polymorphism of bacteriophage T7. Journal of Molecular Biology. 1997; 273(3): 658–667p.

Cars O, Högberg LD, Murray M. Meeting the challenge of antibiotic resistance. British Medical Journal. 2008; 337: 726–728p.

Haq IU, Chaudhary WN, Akhtar MN, Andleeb S, Qadri I. Bacteriophages and their implications on future biotechnology: A review. Virology Journal. 2012; 9(1): 1-8p.

Zhu C, Xiong H, Han J, Cui B, Piao D, Lii Y, Jiang H, Ren Q , Ma X, Chai Y, Huang X, Zhao H, Li L. Molecular characterization of Tb: A new approach for an ancient Brucellaphage. International Journal of Molecular Sciences. 2009; 10: 2999–3011p.

Chachra D, Kaur H, Chandra M, Saxena HM. Isolation, electron microscopy and physiochemical characterization of a Brucellaphage against Brucella abortus vaccine strain S19. The Internet Journal of Microbiology. 2012; 10(2): 121–128p.

Jain L, Kumar V, Chachra D, Tiwari AK. Morphological and Molecular Characterization of Indian isolate of Brucellaphage. Journal of Pure and Applied Microbiology. 2014; 8(5): 4087–4097p.

Gupta V, Saxena HM. Isolation and characterization of BpL1, a broad acting lytic bacteriophage against Brucella. Int J Curr Microbiol App Sci. 2017; 6(11): 2486–2496p. doi: https://doi.org/10.20546/ijcmas.2017.611.292

Douglas JT, Elberg SS. Isolation of Brucella melitensis phage of broad biotype and species specificity. Infection and Immunity. 1976; 14(1): 306–308p.

Chachra D, Kaur P, Siddavatam P, Suravajhala P, Saxena HM. On genome annotation of Brucellaphage Gadvasu (BpG): Discovery of ORFans for integrated systems biology approaches. Systems and Synthetic Biology. 2015; 9(1): 57–62p.

Morris JA, Corbel MJ, Philip JIH. Characterization of three phages lytic for Brucella species. Journal of General Virology. 1973; 20: 63–73p.

Drozevkina MS. The present position in brucellphage research. Bull Org Mond Santé Bull Wild Hlth Org. 1963; 29: 43–57p.

Parnas J, Feltynowski A, Bulikowski W. Anti-Brucellaphage. Nature. 1958; 182: 1610–1611p.

Corbel MJ, Thomas EL. Description of a new phage lytic for several Brucella species. Journal of Biological Standardization. 1976; 4(3): 195–201p.

Pandey S, Chachra D, Chandra M, Saxena HM. Protein profiling and physic-chemical characterization of an isolated phage against Brucella abortus strain 19. African Journal of Microbiology Research. 2013; 7(14): 1233–1238p.

Prajapati A, Ramachandran D, Verma H, Abbas M, Rawat M. Therapeutic efficacy of Brucellaphage against Brucella abortus in mice model. Veterinary World. 2014; 7(1): 34–37p.

Hammer IJA, Al Dahouk S, Nockler K, Gollner C, Appel B, Hertwig S. F1 and Tbilisi are closely related Brucella phages exhibiting some distinct nucleotide variations which determine the host specificity. Genome. 2014; 2(1): 1–2p.

Morgan WJ. Brucellosis in animals: Diagnosis and control. Proceedings of Royal Society of Medicine. 1969; 62: 1050–52p.

Calderone JG, Pickett MJ. Characterization of Brucellaphage. Journal of General Microbiology. 1965; 39: 1–10p.

Corbel MJ, Tolari F, Yadava VK. Characterization of a new phage lytic for both smooth and non-smooth Brucella species. Research in Veterinary Science. 1988; 44(1): 45–49p.

Morris JA, Corbel MJ. Properties of a new phage lytic for Brucella suis. Journal of General Virology. 1973; 21: 539–554p.

Sulakvelidze A, Alavidze Z, Morris J. Bacteriophage therapy. Antimicrobial Agents and Chemotherapy. 2001; 45: 649–659p.

Matsuzaki S, Rashel M, Uchiyma J, Ujihara T, Kuroda M, Ikeuchi M, Fujieda M, Wakiguchi J, Imai S. Bacteriophage therapy: A revitalized therapy against bacterial infectious diseases. Journal of Infection and Chemotherapy. 2005; 11: 211–219p.

Skurnik M, Strauch E. Phage therapy. Facts and fiction. International Journal of Medical Microbiology. 2006; 296: 05–14p.

Hanlon GW. Bacteriophages: An appraisal of their role in the treatment of bacterial infections. International Journal of Antimicrobial Agents. 2007; 30: 118–128p.

Ahmed K, Kaderbhai NN, Kaderbhai MA. Bacteriophage therapy revisited. African Journal of Microbiology Research. 2012; 6(14): 3366–3379p.

Ly-Chaitain MH. The factors affecting effectiveness of treatment in phage therapy. Frontiers in Microbiology. 2014; 5(51): 1–7p.

Arnold L, Weiss E. Isolation of bacteriophage free from bacterial proteins. The Journal of Infectious Diseases. 1925; 37(5): 411–417p.

Larkum NW. Bacteriophage as substitute of typhoid vaccine. Journal of Bacteriology. 1929; 17: 42p.

Compton A. Sensitization and immunization with bacteriophage in experimental plague. Journal of Infectious Diseases. 1928; 43: 448–457p.

Pirisi A. Phage therapy - Advantages over antibiotics? Lancet. 2000; 356: 1418p.

Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM. Evaluation of aerosol spray and intramuscular injection of bacteriophage to treat an Escherichia coli respiratory infection. Poultry Science. 2003; 82: 1108–1112p.

Burrowes B, Harper DR, Anderson J, McConville M, Enright MC. Bacteriophage therapy: Potential uses in the control of antibiotic-resistant pathogens. Expert Review of Anti-infective Therapy. 2001; 9: 775–785p.

Thiel K. Old dogma, new tricks -21st century phage therapy. Nature Biotechnology. 2004; 22: 31–36p.

Deresinki S. Bacteriophage therapy: Exploiting smaller fleas. Clinical Infectious Diseases. 2009; 48: 1096–1101p.

Alisky J, Iczkowski K, Rapoport A, Troitsky N. Bacteriophages show promise as antimicrobial agents. Journal of Infection. 1998; 36: 5–15p.

Wang IN, Smith DL, Young R. Holins: The protein clocks of bacteriophage infections. Annual Review of Microbiology. 2000; 54: 799–825p.

Borysowski J, Weber-Dabrowska B, Gorski A. Bacteriophage endolysins as a novel class of antibacterial agents. Experimental Biology and Medicine. 2006; 231: 366–377p.

Mathur MD, Bidhani S, Mehndiratta PL. Bacteriophage therapy: An alternative to conventional antibiotics. Journal of Association of Physicians of India. 2003; 51: 593–596p.

Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: Rediscovery and renewed assessment of potential. Trends in Microbiology. 1997; 5: 268–271p.

Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotic. Journal of General Microbiology. 1982; 128: 307–318p.

Nakai T, Sugimoto R, Park KH, Matsouka S, Mri K, Nishioka T, Maruyama K. Protective effects of bacteriophage on experimental Lactococcus graviae infection in yellow tail. Disease of Aquatic Organisms. 1999; 37: 33–41p.

Basdew IH, Laing MD. Mini- Review: Biological control of mastitis using bacteriophage therapy. Communicating Current Research and Technological Advances Formatex. 2011; 386–393p.

Payne RJH, Jansen VAA. Understanding bacteriophage therapy as a density-dependent kinetic process. Journal of Theoretical Biology. 2001; 208: 37–48p.

Madera C, Monjardin C, Suarez E. Milk contamination and resistance to processing conditions determine the fate of Lactococcus lactis bacteriophages in diaries. Applied Environmental Microbiology. 2004; 70: 7365–7371p.

Langlet J, Gaboriaud F, Duval JLF, Gantzer C. Aggregation and surface properties of F-specific RNA phages: Implication for membrane filteration process. Water Research. 2008; 42: 2769–2777p.

Merril R, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S. Long-circulating bacteriophage as antibacterial agents. Microbiology. 1996; 93: 3188–3192p.

Chibber S, Kumari S. Application of therapeutic phages in medicine. In: Bacteriophages. USA: Intech. Publications; 2012.

Esber HJ, Ganfiel D, Rosenkrantz H. Staphagelysate an immune modulator of primary immune response in mice. Immunopharmacology. 1985; 10: 77–82p.

Mishra AK, Rawat M, Viswas KN, Abhisek, Kumar S, Reddy M. Expression and lytic efficacy assessment of Staphylococcus aureus phage SA4 lysin gene. Journal of Veterinary Science. 2012; 14(1): 37–43p.

Pasterneck. Method for vaccination of poultry by bacteriophage lysate bacterin. US Patent 2009/ 0297561 A1; 2009.

Ryan EM, Gorman SP, Donnelly RF, Gilmore BF. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. Journal of Pharmacy and Pharmacology. 2011; 63: 1253–1264p.

Yilmaz C, Colak M, Yilmaz BC, Ersoz G, Kutateladze M, Gozlugol M. Bacteriophage therapy in implant related infections. The Journal of Bone and Joint Surgery. 2013; 95: 117–125p.

Morris JA. Investigation of the effect of Brucellaphage on the course of experimental infection with Brucella abortus. British Veterinary Journal. 1980; 136: 278–289p.

Jain L, Rawat M, Prajapati A, Tiwari AK, Kumar B, Chaturvedi VK, Saxena HM, Ramakrishnan S, Kumar J. Protective immune response of aluminium hydroxide gel adjuvanted phage lysate of Brucella abortus S19 in mice against direct virulent challenge with B. abortus 544. Biologicals. 2015; 43(5): 369–376p.

Jain L, Rawat M, Ramakrishnan S, Kumar B. Active immunization with Brucella abortus S19 phage lysate elicits serum IgG that protects guinea pigs against virulent B. abortus and protects mice by passive immunization. Biologicals. 2017; 45: 27–32p.

Mohan A, Saxena HM. Effects of Bacteriophage Therapy on Host Immune Responses in Brucellosis Affected Cattle. Acta Scientific Microbiology. 2020a; 3(6): 146–151p.

Mohan A, Saxena HM. Effect of phage targeting therapy of brucellosis on host antibody response in cattle. PHAGE: Therapy, Applications, and Research. 2020b; 1(4): 223–229p.

Saxena HM, Raj S. A novel immunotherapy of Brucellosis in cows monitored non-invasively through a specific biomarker. PLOS Neglected Tropical Diseases. 2018; 12(4): e0006393. Available at: https://doi.org/10.1371/journal.pntd.0006393.


Refbacks

  • There are currently no refbacks.